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On the occasion of the installation ofa new editor and title for the jour-
nal, it is perhaps appropriate to also
consider new approaches to the treat-
ment of lung cancer (LC).
Shockingly little progress has
been made over the past 25 years in
improving outcomes for people with
LC. During this interval, relative 5-year
survival for patients with non–small-cell
LC (NSCLC) has improved only from
12% to 15%, and all-cause survival is
only 9%.1 How can such dismal results
continue to generate optimism and self-
congratulation?
I suggest that the idea at the root
of this catastrophe is a master plan that
can be succinctly categorized as a late-
detection, multimodality salvage strat-
egy (LDMMS). No effort is made to
diagnose LC until the presentation of a
symptomatic patient. Only then are at-
tempts made to cure the inevitable ad-
vanced-stage disease using MMS. It
should be immediately evident that, for
LDMMS to succeed, we need treatment
that reliably cures stage III-IV NSCLC
because 40% of patients with NSCLC
present with stage IV disease (60% in
poor people) and 30 to 35% with stage
III disease.2
We have no curative treatment for
these patients. Although innumerable
experiments show improved survival
measured in months, long-term stage IV
survival remains rare. Stage IIIB results
are only marginally better, and most
patients with stage IIIA disease die.
Rather than change strategy, LC
“thought leaders” continue to congratu-
late one another and channel research
dollars into still further efforts to cure
advanced-stage LC with drugs, in the
process diverting funding away from
primary prevention, smoking cessation,
and early detection.
The result of obstinate adherence
to the LDMMS strategy is calamitous.
Although innumerable publications re-
port 100% fatality, the response of
thought leaders persists unchanged.
More research is needed to study molec-
ular mechanisms of LC and translate
this information into new drug develop-
ment. When the new drugs fail as mono-
therapy, combinations of doublets, trip-
lets, and quadruplets are tried ad
infinitum. At what point should one
view LDMMS not as noble struggle, but
as stubborn lack of vision? Is there an
escape from repetitive cycles of mis-
guided optimism, narrow focus, and in-
evitable futility?
Striking improvements in survival
for solid organ cancers followed the ini-
tiation of early detection measures.
Breast cancer, considered hopeless 40
years ago, is now routinely cured in
patients whose disease is detected early.
A new study in Cancer concludes that
61% of improved breast cancer survival
is attributable to treatment of smaller
tumors.3 Experience with cervical, co-
lon, and prostate cancers is similar. Af-
ter decades in obscurity, lung cancer
screening (LCS) research now demon-
strates that protocols based on low-dose,
noncontrast, spiral computerized tomog-
raphy can detect LC effectively in early
stages, when high cure rates are attained
by surgical therapy alone.4–6 Rather
than joyful ovation and clamor for early
implementation, new LCS approaches
have been greeted with apathy, disbe-
lief, and sometimes frank hostility.7 Ep-
idemiologists continue to advocate pre-
posterous alternative hypotheses, e.g.,
that there are large numbers of non-
lethal LC, that LCS will cause enormous
harm, and that research funding for LCS
should be withdrawn. A prominent med-
ical oncologist recently told audiences
that “we can’t afford to screen for lung
cancer; we need the money for treat-
ment.”
In my view, there is rapidly accu-
mulating, compelling evidence that LCS
holds great promise. Recent experience
with postoperative adjuvant chemother-
apy for stage IB NSCLC suggests that
treatment protocols derived from
LDMMS research have improved re-
sults in earlier stages of disease.8 A
revolution in the approach to LC re-
search, education, and treatment is nec-
essary. We must accept the fact that sole
reliance on LDMMS has been an abject
failure and that it realistically offers lit-
tle prospect for a major breakthrough in
the foreseeable future. In addition to
stronger efforts in tobacco control,
smoking cessation, and chemopreven-
tion, we must prioritize screening proto-
cols for individuals at high risk of LC,
and we need to do so immediately.
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